Top Biotech Companies With Best Stability & Growth (3,630)

Strong Revenue Growth: Galleri and total revenue have risen consistently, with full-year 2025 up 17% and U.S. Galleri up 26%, followed by Q1–Q2 2026 total revenue gains of 28% and 26% alongside 50% and 35% volume growth. This cadence, including Q4 2025 Galleri revenue up 31%, indicates sustained commercial momentum after the June 2024 spin‑off.

Strategic Partnerships: Channel and platform integrations such as Epic EHR and Quest Diagnostics, plus collaborations like Samsung for Asian commercialization, are expanding access and streamlining ordering. Additional distribution wins (e.g., Priority Health employer plans and digital health channels) reinforce multi‑channel penetration for Galleri.

Investor Backing & Capital Strength: The company reports a substantial cash balance (~$861.6M as of Q2 2026) and closed a $110M equity financing with Samsung, bolstering financial flexibility. Public listing post‑spin‑off further enhances capital‑markets access to fund trials and commercialization.

Strong Revenue Growth: Revenue is accelerating, with FY2025 up 19% year over year and Q4 2025 up 22%, followed by Q1 and Q2 2026 growth of 22% and 27%. Guidance for 2026 was raised to $94–$96 million, implying 22%–24% growth.

Strategic Partnerships: Collaborations with Mount Sinai (April 2026), Memorial Sloan Kettering (June 2026 precision medicine hub), and an expanded AstraZeneca alliance (August 2025) are highlighted as supporting platform adoption and data generation. Several large BioPharma contracts signed into late 2025/early 2026 further reinforce traction.

Customer Loyalty & Retention: Spending within the installed base is rising, with net dollar retention improving to 115% in 2025 and 117% in the first quarter of 2026. This coincides with rising analysis volumes across 2025–2026.

Investor Backing & Capital Strength: Recent financings include a strategic Series C with Dassault Syst�fsmes/Medidata (March 2025) and a Series D in April 2026 led by Boehringer Ingelheim tied to CT-155 commercialization. The restructuring with Boehringer also involved additional funding as commercialization responsibilities shifted to Click.

Product Line Growth: FDA authorizations for Rejoyn (MDD, 2024) and CT-132 (migraine prevention, 2025), plus the acquisition of AspyreRx (type 2 diabetes), expand the marketed and near-market portfolio. The launch of "Click SE" and CT-155s Breakthrough designation and positive pivotal data further broaden the offering toward potential submission.

Strategic Partnerships: Collaborations with Boehringer Ingelheim, Otsuka, and Dassault Syst�fsmes/Medidata, along with a 2026 venture with Ultrahuman, indicate strong external validation and routes to commercialization. Partner activity includes Boehringer transferring commercialization duties for CT-155 to Click.

Investor Backing & Capital Strength: Formation Bio closed a $372M Series D on June 26, 2024 led by a16z with significant participation from Sanofi, bringing total funding to over $600M and at a material step-up in valuation. The capital is directed toward expanding its drug pipeline and AI platform.

Strategic Partnerships: A first‑in‑class AI collaboration with Sanofi and OpenAI (announced May 2024) has already produced Muse, an AI tool for patient recruitment. Additional partnering activity includes Sanofi’s 2025 deal for gusacitinib via a Formation subsidiary, signaling expanding commercial and technology ties.

Product Line Growth: Multiple in‑licensing moves in 2025–2026 (e.g., a CNS‑penetrant TYK2 inhibitor, a miR‑124 activator, and an anti‑CD226 program) broaden the portfolio. The first participant was dosed in a Phase 1 trial (BLKR201) on June 9, 2026, marking concrete clinical progression.

Strong Revenue Growth: Revenue expanded rapidly, with FY2025 up 83% to about $1.27B and Q1/Q2 2026 up 36% and 22% year over year, respectively. Management also raised 2026 revenue guidance to approximately $1.595–$1.605B.

Diversified Revenue Streams: Both Diagnostics and Data & Applications are expanding, with Diagnostics up 34.7% in Q1 and 20% in Q2 2026 and Insights/data licensing up 36% in Q2 alongside about $200M in new licenses. Rising oncology test volumes (28–31% YoY) and accelerating MRD tests (~4,700 in Q4 2025 to ~9,000 in Q2 2026) reinforce multiple growth engines.

Profitability: The company achieved its first GAAP-profitable quarter in Q2 2026 (net income about $5.6M; Adjusted EBITDA ~$8.0M). Guidance points to further improvement in 2026, indicating progress toward sustained profitability.

Market Expansion: Public materials indicate the platform footprint has grown to 6,000+ research sites and 25+ sponsors, up from 5,500+ sites cited in late 2025, suggesting continued expansion into 2026. Geographic reach and site participation are portrayed as broadening across dozens of countries.

Strategic Partnerships: Collaborations with large biopharma (e.g., Sanofi, including a 2026 portfolio-level discussion) and integrations with ecosystem vendors like CRIO, RealTime-Devana, and eClinPro signal commercial traction and deeper ecosystem ties. These relationships are positioned to increase marketplace activity and data depth for sponsors and sites.

Innovation-Driven Growth: AI-powered pre-screening and workflow tooling launched in 2025 with ongoing case studies and integrations in 2026, aimed at accelerating enrollment and reducing site burden. The continued rollout of AI features and workflow enhancements suggests rising product maturity and adoption.

Strong Revenue Growth: Total revenue increased to $255.9M in 2025 with software up and drug‑discovery more than doubling, while operating expenses declined year over year. Early 2026 also showed momentum, with first‑half revenue modestly higher and Q2 posting year‑over‑year growth.

Strategic Partnerships: New and expanded agreements—such as Bristol Myers Squibb deploying Bunsen and a July 2026 discovery collaboration with Simcere—broaden platform use and collaboration optionality. The Lilly/Ajax transaction also validated the model and supported a higher 2026 drug‑discovery outlook.

Product Line Growth: The introduction of Bunsen, an agentic AI co‑scientist, expands the software portfolio and is being deployed at scale within BMS. This product push complements growth in ACV and broader platform adoption.

Market Expansion: International partnerships across the UK, Germany, and Japan—culminating in a first Scottish agreement in 2026—are described as tripling the network in 2025 and adding nearly 70% ex‑U.S. growth in 2026. These moves indicate a materially broader geographic footprint for evidence generation.

Strategic Partnerships: Collaborations with organizations such as NHS Greater Glasgow and Clyde, Quest Diagnostics, Abbott, TailorMed, and Unicancer reflect deepening integration at the point of care and with research stakeholders. These relationships suggest expanding routes to market and data acquisition.

Product Line Growth: New offerings like Flatiron Telescope, AI‑powered oncology datasets, and an AI data‑quality/validation framework signal active investment in products and capabilities. Conference acceptances at ISPOR/ASCO/WCLC in 2026 further underscore ongoing commercialization and scientific engagement.

Innovation-Driven Growth: New AI-focused capabilities (e.g., AI Connectors built on Model Context Protocol) and a stated push to be an “AI platform for biotech R&D” signal ongoing product investment. Reported usage of Benchling AI across 500 biotech companies underscores adoption of these innovations.

Strategic Partnerships: The January 2026 collaboration with Lilly’s TuneLab is positioned to bring proprietary models to scientists across Benchling’s customer base. Acqui-hires of ReSync Bio and Sphinx Bio in 2025 were used to accelerate the AI roadmap.

Strong Revenue Growth: ARR was independently estimated around the low-$200 millions by mid-2024 with year-over-year increases, indicating continued top-line expansion. While the pace has moderated versus earlier years, the trajectory remains positive.

Product Line Growth: Launched and acquired products are expanding at a double‑digit pace (e.g., +18% operational in Q2 2026), led by assets such as Eliquis, Padcev, the Vyndaqel family, and Lorbrena. Excluding Comirnaty and Paxlovid, revenue grew mid‑single digits, signaling healthy momentum in the core portfolio.

Cost & Operational Efficiency: A multi‑year cost realignment targets about $5.7B in net savings by end‑2026, with a further $2.5B in productivity gains planned for 2027–2029. These actions have supported improved adjusted earnings even as headline revenue normalizes post‑COVID.

Innovation-Driven Growth: A robust late‑stage pipeline and oncology expansion following the Seagen acquisition underpin future growth, with numerous pivotal study starts in 2025–2026. Company commentary highlights oncology and obesity programs as key catalysts into the back half of the decade.

Strong Revenue Growth: Revenue and test volumes have risen sharply through 2025 and Q1 2026, and management repeatedly raised 2026 guidance. Margin improvement alongside record oncology volumes reinforces top-line momentum.

Strong Market Position & Advantage: Natera is cited as the U.S. NIPT volume leader and a prominent, Medicare-covered front‑runner in tumor‑informed MRD, with co‑leadership in transplant dd‑cfDNA. These entrenched positions reflect broad clinician adoption and payer coverage.

Innovation-Driven Growth: Advances such as Signatera Genome Medicare coverage, an FDA CDx approval in bladder cancer, and the Foresight acquisition, plus extensive peer‑reviewed data, are expanding clinical utility and adoption. Product enhancements in women’s health and ongoing evidence generation further support growth.

Profitability: Adjusted EPS and operating margins expanded despite muted top-line trends, including a 31.1% adjusted operating margin in the most recent quarter. Cost and productivity actions supported margin improvement even as sales were flat year over year.

Strong Market Position & Advantage: Leadership in niches such as immunoassays and high-quality proteins (R&D Systems), RNA-ISH (RNAscope), and automated protein analysis (ProteinSimple) underpins competitive strength. In-house manufacturing control over most reagents reinforces quality and consistency across core categories.

Future-Ready Strategy: Focus on cell therapy, proteomic instrumentation, spatial biology, and precision diagnostics has expanded as a share of revenue and aligns with high-growth workflows. Acquisitions and strategic stakes (e.g., Lunaphore, Wilson Wolf/ScaleReady) position the portfolio for emerging demand.